COVID-19 |

The Respiratory Integrative Biology and Translational Research (RIBT) study section reviews integrative, translational as well as patient oriented research involving pulmonary vascular biology and disease, neural control of breathing, respiratory biophysics and biomechanics, imaging of lung and chest wall, and upper airway physiology and control of respiration during sleep. Clinical studies and trials related to pulmonary physiology are reviewed in RIBT. Methods may include molecular and cellular approaches, normal and genetically modified animal models, human subjects and mathematical modeling. Emphasis is often on physiologic, integrative, and translational approaches, including combining model simulations with experiments, interactions between and across tissues and cell types, and hierarchical approaches that link micro- and macro-level responses.

The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.


  • Pulmonary vascular biology and disease:
    • pulmonary hypertension
    • angiogenesis
    • normal and abnormal endothelial and vascular smooth muscle cell biology
    • mechanisms of vasoreactivity,barrier function of the vascular cells in relation to lung fluid balance
    • lung injury when the focus is on vascular function
    • the involvement of reactive oxygen and nitrogen species as well as hypoxia in these processes
  • Neural control of breathing:
    • central and peripheral chemoreceptors
    • central neural processes, airway receptors
  • Respiratory biophysics, biomechanics, and imaging of the lung and chest wall:
    • mechanical ventilation, application of imaging techniques
    • aerosol inhalation,gas transport
  • Upper airway physiology and control of respiration:
    • normal and abnormal breathing during sleep (e.g., SIDS, obstructive sleep apnea)
  • Clinical studies related to normal and abnormal pulmonary physiology:
    • phase 1 and 2 clinical trials as well as single site phase 3 trials
    • genetic studies when combined with an investigation of the physiology of lung disease

Shared Interests and Overlaps

There are shared interests between RIBT and Lung Injury, Repair, and Remodeling (LIRR): While studies involving pulmonary endothelial cells may be reviewed in RIBT, those where epithelial cells are involved may be reviewed in LIRR. Studies which focus on stem cells for lung injury & repair may be reviewed in LIRR.

There are shared interests between RIBT and Infectious, Reproductive, Asthma and Pulmonary Conditions (IRAP). Applications which focus on identifying genes associated with asthma, or studies that aim to investigate mucin production, airway hyperreactivity and granulocytes may be reviewed in IRAP.

There are shared interests between RIBT and Lung Cellular, Molecular and Immunobiology (LCMI). Studies that focus on host inflammatory responses associated with lung function may be assigned to LCMI while applications which focus on pulmonary vascular disorders are more appropriately reviewed in RIBT.

There are shared interests between RIBT and Genetics of Health and Disease (GHD). While applications which generally focus on pulmonary vascular biology and related diseases may be reviewed in RIBT, studies focused on the genetics, genomics, epigenetics, or GWAS of lung disease may be reviewed in GHD.

There are shared interests between RIBT and Integrative Myocardial Physiology/Pathophysiology A (MPPA). While applications which generally focus on pulmonary conditions, including pulmonary hypertension, may be reviewed in RIBT, studies of pulmonary conditions which focus on models of right ventricular heart failure may be reviewed in MPPA. ​